Neuland Laboratories Limited (NEULANDLAB) — Corporate Action
Neuland Laboratories reported FY2025-26 audited financials showing revenue of [amount not verified] and net profit of [amount not verified], with a proposed final dividend of ₹34 per share (340% payout). The board approved capacity expansion at Telangana Unit 1 requiring ₹143.4 crores investment, and appointed Dr. Mauricio Futran as Additional Director pending shareholder approval at the August 4 AGM.
About Neuland Laboratories Limited (NEULANDLAB)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when NEULANDLAB files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track NEULANDLAB — Free💡 Ask AI about this filing
📊 More NEULANDLAB filings
- share transfer — 2 July 2026 Neuland Laboratories Limited received a SEBI-mandated certificate from its share transfer agent, Kfi...
- Financial Results — 25 June 2026 Neuland Laboratories Limited announced that its trading window will close on July 1, 2026, and remai...
- Announcement — 3 June 2026 Neuland Laboratories announced its participation in the Nuvama India Conference 2026 in London on Ju...
- Announcement — 31 May 2026 Neuland Laboratories announced its management will attend a BOFA Healthcare Tour investor meeting in...
- Announcement — 22 May 2026 Neuland Laboratories announced its management will attend the 16th Annual Investor Conference hosted...
🔥 Also filed on 12 May 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when NEULANDLAB files new disclosures
Track NEULANDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track NEULANDLAB — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research